Study of a new drug injected into tumors for breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a drug called mitazalimab injected directly into the tumor for patients with early-stage or recurrent breast cancer who are scheduled for surgery. The goal is to see if this approach can help the immune system fight the cancer before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have breast cancer that hasn't spread to other parts of the body and you are planning to have surgery as your first treatment.
- You are at least 18 years old and weigh between 40 and 110 kg.
- You have a tumor sample available for testing and are willing to have it studied.
- Your surgery will be at a University of Pennsylvania Hospital.
- You are generally healthy enough for surgery and have not had certain prior treatments like CD40 or anti-PD-1 therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
This trial tests whether giving nivolumab before surgery (neoadjuvant treatment) can improve outcomes for people with certain resectable breast cancers. It focuses on tumor types linked to immune activity (like triple-negative and specific lab markers).
This Phase 2 study looks at how well early breast cancer shrinks with treatment and how that matches with what doctors find after surgery under the microscope. The goal is to learn better ways to predict and assess treatment success.
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
This Phase 2 study checks whether adding a personalized (biomarker-matched) medicine after standard chemotherapy and surgery lowers the risk of breast cancer coming back. Your study drug choice depends on tumor test results (from your tumor’s genetics and immune markers).
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.